10-Q: Manhattan Scientifics Reports Q1 2024 Results with Net Loss of $382,000

Manhattan Scientifics reported a net loss of $382,000 for the first quarter of 2024, an improvement compared to the $420,000 loss in the same period last year.

Summary

• Manhattan Scientifics, Inc. reported a net loss of $382,000 for the three months ended March 31, 2024, compared to a net loss of $420,000 for the same period in 2023.
• The company's operating expenses were $192,000, including $189,000 in general and administrative costs and $3,000 in research and development.
• The loss from operations was $192,000, while other expenses totaled $190,000, primarily due to a loss on fair value adjustment of investments.
• The company's cash and cash equivalents decreased by $16,000 during the quarter, ending at $51,000.
• Manhattan Scientifics has a working capital deficit of $2,215,000 and an accumulated deficit of $72,797,000 as of March 31, 2024.
• The company's ability to continue as a going concern is dependent on generating cash from the sale of common stock, obtaining debt financing, and achieving profitable operations.
• The company is seeking to raise additional working capital through licensing its technology and generating revenue from other services.
• The company holds 591,662 shares of Imagion Biosystems, with a fair value of approximately $29,000 as of March 31, 2024.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a net loss, working capital deficit, and going concern issues. While there is a slight improvement in net loss compared to the previous year, the overall outlook is negative due to the company's dependence on raising additional capital and the lack of revenue.

Positives

• The net loss decreased by $38,000 compared to the same quarter last year.
• The company generated $26,000 in cash from investing activities due to the sale of Imagion shares.

Negatives

• The company has a significant working capital deficit of $2,215,000.
• The company's cash and cash equivalents decreased by $16,000 during the quarter.
• The company has an accumulated deficit of $72,797,000.
• The company recorded a $190,000 loss on fair value adjustment of investments.
• The company's ability to continue as a going concern is in doubt.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• There is no assurance that the company will be able to generate sufficient cash flow from operations.
• The company may not be able to obtain additional financing on acceptable terms.
• The company faces significant competition in its industry.
• The company's intellectual property may not be adequately protected.
• The company has a material weakness in internal controls over financial reporting.

Future Outlook

The company anticipates royalty income as the nanotitanium is commercialized for use in medical prosthetics and plans to raise additional working capital through licensing its technology and generating revenue from other services. The company believes its current cash position may not be sufficient to maintain operations for the next twelve months and may need to engage in equity or debt financing.

Management Comments

• Management believes that the unaudited interim financial statements include all adjustments necessary for a fair statement of the results for the interim period presented.
• Management intends to raise additional working capital through the continued licensing of its technology as well as to generate revenues for other services.
• Management's plan includes selling equity securities and/or obtaining debt financing to fund capital requirements and ongoing operations.

Industry Context

Manhattan Scientifics operates in the technology transfer and commercialization space, focusing on nanotechnology. The company's performance is influenced by its ability to secure licensing agreements, protect its intellectual property, and successfully commercialize its technologies. The company's financial results reflect the challenges of early-stage technology development and commercialization.

Comparison to Industry Standards

• Manhattan Scientifics is a small, early-stage technology company, making direct comparisons to large, established companies difficult.
• The company's lack of revenue and significant losses are not uncommon for companies in the early stages of technology development.
• The company's reliance on licensing agreements for revenue is a common strategy for technology incubators.
• The company's investment in Imagion Biosystems is similar to other early-stage investments in the biotechnology sector, where valuations can fluctuate significantly.
• The company's need for additional capital is typical for companies in this stage of development, and the risks associated with raising capital are common.

Related Party Transactions

• As of March 31, 2024, the Company had accrued expenses to related parties of approximately $2,048,000, including amounts due to the company's sole officer, chairman of the board, and members of the board of directors.

Stakeholder Impact

• Shareholders face the risk of significant dilution if the company raises additional capital through equity issuances.
• Employees may be impacted by the company's financial instability and potential need for cost-cutting measures.
• Customers and suppliers may be affected by the company's ability to continue operations and fulfill its obligations.
• Creditors face the risk of non-payment if the company is unable to secure additional financing or generate sufficient revenue.

Next Steps

• The company intends to raise additional working capital through licensing its technology and generating revenue from other services.
• The company may need to engage in equity or debt financing to secure additional funds.
• The company will continue to seek to identify emerging technologies through strategic alliances.

Key Dates

Keywords

Manhattan Scientifics, financial results, Q1 2024, net loss, working capital, Imagion Biosystems, technology licensing, nanotechnology, going concern, capital raise